Financials Nanalysis Scientific Corp.

Equities

NSCI

CA63000Y1034

Advanced Medical Equipment & Technology

Delayed Toronto S.E. 07:27:50 10/05/2024 pm IST 5-day change 1st Jan Change
0.485 CAD +2.11% Intraday chart for Nanalysis Scientific Corp. +10.23% +29.33%

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024
Capitalization 1 31.37 111.4 68.83 38.08 53.69
Enterprise Value (EV) 1 31.37 111.4 68.83 38.08 53.69
P/E ratio -7.92 x - - - -
Yield - - - - -
Capitalization / Revenue - 6.94 x 2.77 x 1.34 x 1.57 x
EV / Revenue - 6.94 x 2.77 x 1.34 x 1.57 x
EV / EBITDA - 58.5 x -17.5 x -4.72 x -21.5 x
EV / FCF - - - - -
FCF Yield - - - - -
Price to Book - 4.68 x - - -
Nbr of stocks (in thousands) 66,035 76,829 94,282 1,01,544 1,13,027
Reference price 2 0.4750 1.450 0.7300 0.3750 0.4750
Announcement Date 22/04/21 28/04/22 27/04/23 29/04/24 -
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024
Net sales 1 - 16.04 24.82 28.47 34.1
EBITDA 1 - 1.905 -3.935 -8.074 -2.5
EBIT - - - - -
Operating Margin - - - - -
Earnings before Tax (EBT) - - - - -
Net income -3.678 - - - -
Net margin - - - - -
EPS -0.0600 - - - -
Free Cash Flow - - - - -
FCF margin - - - - -
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 22/04/21 28/04/22 27/04/23 29/04/24 -
1CAD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 3.336 5.077 5.554 5.187 6.878 7.203 4.674 6.956 7.036 9.8 7.4 7.2 8.6 10.9
EBITDA 1 0.012 0.413 0.21 -0.947 -0.618 -2.58 -3.547 -2.399 -1.354 -0.774 -1.2 -0.7 -0.3 0.1
EBIT - - - - - - - - - - - - - -
Operating Margin - - - - - - - - - - - - - -
Earnings before Tax (EBT) - - - - - - - - - - - - - -
Net income - - - - - - - - - - - - - -
Net margin - - - - - - - - - - - - - -
EPS - - - - - - - - - - - - - -
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 18/11/21 28/04/22 30/05/22 25/08/22 29/11/22 27/04/23 25/05/23 24/08/23 29/11/23 29/04/24 - - - -
1CAD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024
Net Debt - - - - -
Net Cash position - - - - -
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - - - - -
ROE (net income / shareholders' equity) - -9.25% - - -
ROA (Net income/ Total Assets) - - - - -
Assets - - - - -
Book Value Per Share - 0.3100 - - -
Cash Flow per Share - -0.0200 - - -
Capex - 0.6 - - -
Capex / Sales - 3.71% - - -
Announcement Date 22/04/21 28/04/22 27/04/23 29/04/24 -
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.475 CAD
Average target price
1.2 CAD
Spread / Average Target
+152.63%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. NSCI Stock
  4. Financials Nanalysis Scientific Corp.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW